Navigation Links
Governor Cuomo Announces Continued Growth at Roswell Park Cancer Institute with Regional Economic Development Council Funding; RPCI Center for Personalized Medicine established with CTG (NASDAQ: CTGX) serving as its technology partner
Date:1/31/2013

market, CTG offers hospitals, physician groups, and regional health information exchanges a full range of electronic medical record services. Additionally, CTG has developed for the healthcare provider and payer markets unique, proprietary medical management and claims analytics software solutions that support better and lower cost healthcare. CTG also provides managed services IT staffing for major technology companies and large corporations. Backed by over 45 years' experience, proprietary methodologies, and an ISO 9001-certified management system, CTG has a proven track record of delivering high-value, industry-specific solutions. CTG generated revenue of $396 million in 2011 and operates in North America and Western Europe. CTG posts news and other important information on the Web at www.ctg.com.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI's website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

NOTE TO EDITORS:  A version of this press release was issued January 30, 2013, by the Office of New York State Governor Andrew M. Cuomo .


'/>"/>
SOURCE Roswell Park Cancer Institute; CTG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. The Acta Materialia Inc Announces New Chairman of the Board of Governors
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenexâ„¢ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCHâ„¢ developed ... an otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, ...
(Date:8/27/2015)... Poway, CA (PRWEB) , ... August 27, 2015 ... ... a unique opportunity for venture capital funds, investment firms and animal health companies ... the Forum have raised $160 million. Several have also received licensing agreements or ...
(Date:8/27/2015)...  Neogen Corporation (NASDAQ: NEOG ) announced today ... United Kingdom -based Lab M Holdings, a developer, ... systems. Lab M was founded in ... microbial testing and diagnostic products for the global food, ... sells into more than 70 countries worldwide, and has ...
(Date:8/27/2015)... , Aug. 27, 2015 The ... a patient,s eyes—and life—were saved by doctors at Vanderbilt ... working with NNFF, NovaBay Pharmaceuticals and Dr. John ... Center at Seton Medical Center in ... treatment used a breakthrough approach, pioneered by Dr. Crew, ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") ... has dosed the first patient in its Phase ... University of California, San Diego ("UCSD"), ... Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare ...
... Interim Primary Endpoint Data from Phase II Study Shows 71% ... Docetaxel - , , - Secondary Endpoint Evaluation Shows ... Cohort - , , ORLANDO, Fla. and TUSTIN, Calif., ... ) today announced that preliminary results from a Phase II ...
... Clinical Oncology , , ORLANDO, Fla., June 1 ... use of ChemoFX(R), a chemosensitivity assay, to predict the ... of individual patients. Results from the study show ... percent were responsive to cetuximab, a result that is ...
Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... initial tests on a substance that acts as a ... prospects for wider use of the fungus as a ... crops. "Our finding is especially important for the environment ... this will help to reduce dependence on chemical pesticides," ...
... 8, 2010 A team led by a Scripps Research Institute ... is required for memory formation in Drosophila , ... humans, shedding light on neurological disorders such as Alzheimer,s disease or ... 9, 2010 edition (Vol. 67, No. 5) of the journal ...
... three out of four cats in a new study wore ... will tolerate a collar even if their owners are skeptical ... of cases, the animals, tolerance of collars exceeded owners, expectations ... trouble. The researchers suggest that, armed with this data, ...
Cached Biology News:Team led by Scripps Research scientist identifies new gene for memory 2Team led by Scripps Research scientist identifies new gene for memory 3Study: 3 out of 4 cats will wear a collar, making it worth a try 2Study: 3 out of 4 cats will wear a collar, making it worth a try 3